Morpholine

Morpholine

SCHEMBL4472083

C1COCCN1.O=C(O)C(=O)Oc1cccnc1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
ALOX15 P16050 2/20 0.41
ALDH1A1 P00352 5/20 0.40
POLB P06746 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
USP2 O75604 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Niacin SCHEMBL27641687 0.76 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2CHRNB2CHRNA4GAA
SCHEMBL4472090 0.73 MAPT (0.55) MAPTKMT2AMEN1HTTALOX15
Morpholine SCHEMBL16463808 0.73 KDM4E (0.36) MAPTKMT2AMEN1ALDH1A1POLB
Niacinamide SCHEMBL5712729 0.71 F7 (0.67) ALDH1A1POLBSMN1; SMN2CHRNB2CHRNA4
SCHEMBL12271108 0.70 MKNK1 (0.52) KMT2AALOX15ALDH1A1POLBSMN1; SMN2
SCHEMBL29988703 0.70 MKNK1 (0.52) KMT2AALOX15ALDH1A1POLBSMN1; SMN2
SCHEMBL876393 0.70 KMT2A (0.56) MAPTKMT2AMEN1ALOX15ALDH1A1
SCHEMBL31123876 0.70 KMT2A (0.56) MAPTKMT2AMEN1ALOX15ALDH1A1
SCHEMBL13113097 0.70 KMT2A (0.55) MAPTKMT2AMEN1ALOX15ALDH1A1
Hydrochloric Acid SCHEMBL1532934 0.69 MKNK1 (0.51) KMT2AALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
EP-1966132-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-09-10 EP disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, ARRB1 MAPT 3519/4885KMT2A 1738/4885MEN1 4355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.